Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This trial plans to learn more about the effects of a medication, semaglutide, on
cardiovascular function, kidney function, and insulin sensitivity in adults with type 1
diabetes. This medication has been effective in reducing cardiovascular disease and diabetic
kidney disease and improving glucose control and BMI in adults with type 2 diabetes. This
study aims to look at how well the medication works in people with type 1 diabetes.
Semaglutide is not approved by the FDA to be used in this way. These procedures are
considered to be experimental.